Table of Contents
Select a link below to start reading online free!
Front Matter	i-xii
Executive Summary	1-10	(skim)
Introduction	11-16	(skim)
Progress in Vaccine Development	17-38	(skim)
Considerations of Candidate Vaccines	39-52	(skim)
Overview of Analytic Approach and Results	53-92	(skim)
Review of the Analytical Model	93-108	(skim)
Ethical Considerations and Caveats	109-122	(skim)
Observations	123-132	(skim)
References	133-142	(skim)
Appendix 1: Borrelia burgdorferi	143-148	(skim)
Appendix 2: Chlamydia	149-158	(skim)
Appendix 3: Coccidioides Immitis	159-164	(skim)
Appendix 4: Cytomegalovirus	165-172	(skim)
Appendix 5: Enterotoxigenic E. coli	173-176	(skim)
Appendix 6: Epstein-Barr Virus	177-180	(skim)
Appendix 7: Helicobacter pylori	181-188	(skim)
Appendix 8: Hepatitis C	189-194	(skim)
Appendix 9: Herpes Simplex Virus	195-206	(skim)
Appendix 10: Histoplasma capsulatum	207-212	(skim)
Appendix 11: Human Paillomavirus	213-222	(skim)
Appendix 12: Influenza A and B	223-232	(skim)
Appendix 13: Insulin-Dependent Diabetes Mellitus	233-238	(skim)
Appendix 14: Melanoma	239-244	(skim)
Appendix 15: Multiple Sclerosis	245-250	(skim)
Appendix 16: Mycobacterium tuberculosis	251-256	(skim)
Appendix 17: Neisseria gonnorrhea	257-266	(skim)
Appendix 18: Neisseria meningitidis	267-272	(skim)
Appendix 19: Parainfluenza Virus	273-278	(skim)
Appendix 20: Respiratory Syncytial Virus	279-284	(skim)
Appendix 21: Rheumatoid Arthritis	285-290	(skim)
Appendix 22: Rotavirus	291-294	(skim)
Appendix 23: Shigella	295-298	(skim)
Appendix 24: Streptococcus, Group A	299-304	(skim)
Appendix 25: Streptococcus, Group B	305-312	(skim)
Appendix 26: Streptococcus pneumoniae	313-322	(skim)
Appendix 27: Information on accessing Electronic Spreadsheets	323-324	(skim)
Appendix 28: Summary of Workshops	325-434	(skim)
Appendix 29: Questions Posed to Outside Experts and List of Responders	435-442	(skim)
Index	443-460	(skim)

Description

Vaccines have made it possible to eradicate the scourge of smallpox, promise the same for polio, and have profoundly reduced the threat posed by other diseases such as whooping cough, measles, and meningitis.

What is next? There are many pathogens, autoimmune diseases, and cancers that may be promising targets for vaccine research and development.

This volume provides an analytic framework and quantitative model for evaluating disease conditions that can be applied by those setting priorities for vaccine development over the coming decades. The committee describes an approach for comparing potential new vaccines based on their impact on morbidity and mortality and on the costs of both health care and vaccine development. The book examines:

• Lessons to be learned from the polio experience.
• Scientific advances that set the stage for new vaccines.
• Factors that affect how vaccines are used in the population.
• Value judgments and ethical questions raised by comparison of health needs and benefits.
  

The committee provides a way to compare different forms of illness and set vaccine priorities without assigning a monetary value to lives. Their recommendations will be important to anyone involved in science policy and public health planning: policymakers, regulators, health care providers, vaccine manufacturers, and researchers.

Reviews

"...it should be compulsory reading for all who are involved in decision making both at the vaccine development and implementation stages. The individual reader will, however, find it interesting to browse particularly the workshops on the mechanism of actions of some vaccines."
-- Microbiology Today, November 2003

Authoring Organizations

• Institute of Medicine (IOM)
• More Titles from IOM

Search This Book

»Find more like this book

SIGN UP FOR...

New Title Emails
Read about the newest releases and receive special offers.

NOTES

  Downloadable Microsoft Excel 5.0 files: Hypothetical Vaccine X - Spreadsheets